Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

被引:8
作者
Atci, Muhammed Mustafa [1 ]
Geredeli, Caglayan [1 ]
Ay, Seval [2 ]
Sakin, Abdullah [3 ]
Erturk, Biray [4 ]
Secmeler, Saban [1 ]
Arici, Serdar [1 ]
Cekin, Ruhper [1 ]
Yasar, Nurgul [1 ]
Can, Orcun [1 ]
Cihan, Sener [1 ]
Gumus, Mahmut [2 ]
机构
[1] Istanbul Prof Doctor Cemil Tascioglu City Hosp, Clin Med Oncol, Istanbul, Turkey
[2] Medeniyet Univ, Goztepe Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey
[3] Van Training & Res Hosp, Clin Med Oncol, Van, Turkey
[4] Istanbul Prof Doctor Cemil Tascioglu City Hosp, Clin Med Genet, Istanbul, Turkey
关键词
BRCA; breast cancer; Triple-negative; lymphovascular invasion; grade; GERMLINE MUTATIONS; WOMEN; CARCINOMAS;
D O I
10.4274/ejbh.galenos.2020.6346
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study aimed to determine the differences in clinicopathological features of Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer susceptibility genes (BRCA1/2). Materials and Methods: This study enrolled patients with invasive breast cancer who have been evaluated for BRCA1/2 mutations due to the presence of high-risk factors admitted to two tertiary referral centers in Turkey. Clinical and histopathological features were analyzed in BRCA1 mutation carriers, BRCA2 mutation carriers, and non-carriers. Results: A total of 302 patients with a mean age of 44.2 +/- 9.9 (22-82) years were included. BRCA1/2 mutation was found in 75 (24%) patients, of whom 41 (13.6%) were BRCA1 mutation carriers and 37 (12.3%) were BRCA2 mutation carriers. Moreover, 104 (34.4%) and 4 (1.3%) patients had family history of breast and ovarian carcinoma, respectively. The rates of triple negativity (56.1%), histologic grade 3 (65.9%), and lymphovascular invasion (78%) were significantly higher in BRCA1 mutation carriers than in non-carriers and BRCA2 mutation carriers. Furthermore, 87% of triple-negative BRCA1 mutation carriers had histologic grade 3 tumors compared with 38.9% in non-triple-negative BRCA1 mutation carriers, and the difference was significant. Conclusion: Findings of this study showed that BRCA1-related breast cancers represent a distinct group with unique pathological features, which are usually associated with a poor prognosis.
引用
收藏
页码:123 / 127
页数:5
相关论文
共 24 条
[1]   BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].
Alsop, Kathryn ;
Fereday, Sian ;
Meldrum, Cliff ;
deFazio, Anna ;
Emmanuel, Catherine ;
George, Joshy ;
Dobrovic, Alexander ;
Birrer, Michael J. ;
Webb, Penelope M. ;
Stewart, Colin ;
Friedlander, Michael ;
Fox, Stephen ;
Bowtell, David ;
Mitchell, Gillian .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663
[2]   Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer [J].
Atchley, Deann P. ;
Albarracin, Constance T. ;
Lopez, Adriana ;
Valero, Vicente ;
Amos, Christopher I. ;
Gonzalez-Angulo, Ana Maria ;
Hortobagyi, Gabriel N. ;
Arun, Banu K. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4282-4288
[3]   BRCA mutation genetic testing implications in the United States [J].
Bayraktar, Soley ;
Arun, Banu .
BREAST, 2017, 31 :224-232
[4]   Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers [J].
Bayraktar, Soley ;
Jackson, Michelle ;
Gutierrez-Barrera, Angelica M. ;
Liu, Diane ;
Meric-Bernstam, Funda ;
Brandt, Amanda ;
Woodson, Ashley ;
Litton, Jennifer ;
Lu, Karen H. ;
Valero, Vicente ;
Arun, Banu K. .
Breast Journal, 2015, 21 (03) :260-267
[5]   Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers [J].
Byrski, T. ;
Gronwald, J. ;
Huzarski, T. ;
Grzybowska, E. ;
Budryk, M. ;
Stawicka, M. ;
Mierzwa, T. ;
Szwiec, M. ;
Wisniowski, R. ;
Siolek, M. ;
Narod, S. A. ;
Lubinski, J. .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (02) :289-296
[6]   BRCA1/2 Germline Mutations and Their Clinical Importance in Turkish Breast Cancer Patients [J].
Cecener, Gulsah ;
Egeli, Unal ;
Tunca, Berrin ;
Erturk, Elif ;
Ak, Secil ;
Gokgoz, Sehsuvar ;
Tasdelen, Ismet ;
Tezcan, Gulcin ;
Demirdogen, Elif ;
Bayram, Nuran ;
Avci, Nilufer ;
Evrensel, Turkkan .
CANCER INVESTIGATION, 2014, 32 (08) :375-387
[7]   Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study [J].
Copson, Ellen R. ;
Maishman, Tom C. ;
Tapper, Will J. ;
Cutress, Ramsey I. ;
Greville-Heygate, Stephanie ;
Altman, Douglas G. ;
Eccles, Bryony ;
Gerty, Sue ;
Durcan, Lorraine T. ;
Jones, Louise ;
Evans, D. Gareth ;
Thompson, Alastair M. ;
Pharoah, Paul ;
Easton, Douglas F. ;
Dunning, Alison M. ;
Hanby, Andrew ;
Lakhani, Sunil ;
Eeles, Ros ;
Gilbert, Fiona J. ;
Hamed, Hisham ;
Hodgson, Shirley ;
Simmonds, Peter ;
Stanton, Louise ;
Ecclest, Diana M. .
LANCET ONCOLOGY, 2018, 19 (02) :169-180
[8]  
de Bock GH, 2001, BRIT J CANCER, V85, P1347
[9]  
Eisinger F, 1999, INT J CANCER, V84, P263, DOI 10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO
[10]  
2-G